Drug-maker Catalent buys three more Bloomington properties for nearly $1.2 million; recently announced it was hiring up to 600 by end of 2021

The company declined to provide details about its plans for the property. A spokeswoman told The Herald-Times only that the company “continues to invest in our world-class operations in Bloomington to expand capabilities.”

Property transfer records show that Catalent bought the parcels on Oct. 20 from Irvin Materials Inc. IMI, a concrete producer that serves five states including Indiana, did not reply to repeated phone messages.

The Bloomington planning department did not have any plans on file that would indicate what Catalent might do with the property. Planning staff told The Herald-Times that the parcels are zoned “mixed-use employment.” The designation is “intended to provide a mixture of office-related uses and medium-scale multifamily residential uses that provide significant employment opportunities for the community and the surrounding region.”

Catalent careers:Bloomington facility wants to hire 500-600 more employees this year

Catalent announced recently that it plans to hire between 500 and 600 more employees in Bloomington through the end of the year as it was seeing rising demand for its products, which include COVID-19 vaccines.